JP2013524844A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013524844A5 JP2013524844A5 JP2013508489A JP2013508489A JP2013524844A5 JP 2013524844 A5 JP2013524844 A5 JP 2013524844A5 JP 2013508489 A JP2013508489 A JP 2013508489A JP 2013508489 A JP2013508489 A JP 2013508489A JP 2013524844 A5 JP2013524844 A5 JP 2013524844A5
- Authority
- JP
- Japan
- Prior art keywords
- aureus
- protein
- polysaccharide
- recombinant
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 claims 32
- 229920001282 polysaccharide Polymers 0.000 claims 32
- 239000005017 polysaccharide Substances 0.000 claims 32
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108091006036 N-glycosylated proteins Proteins 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 13
- 241000894006 Bacteria Species 0.000 claims 12
- 241000191967 Staphylococcus aureus Species 0.000 claims 8
- 108091035707 Consensus sequence Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 108700023372 Glycosyltransferases Proteins 0.000 claims 4
- 102000051366 Glycosyltransferases Human genes 0.000 claims 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 4
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000002095 exotoxin Substances 0.000 claims 3
- 231100000776 exotoxin Toxicity 0.000 claims 3
- 229960003085 meticillin Drugs 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 claims 2
- 101900127397 Staphylococcus aureus Alpha-hemolysin Proteins 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims 1
- 150000004043 trisaccharides Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33217010P | 2010-05-06 | 2010-05-06 | |
| US61/332,170 | 2010-05-06 | ||
| PCT/EP2011/057111 WO2011138361A1 (en) | 2010-05-06 | 2011-05-04 | Capsular gram-positive bacteria bioconjugate vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016197813A Division JP6435583B2 (ja) | 2010-05-06 | 2016-10-06 | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013524844A JP2013524844A (ja) | 2013-06-20 |
| JP2013524844A5 true JP2013524844A5 (enExample) | 2014-06-26 |
| JP6339366B2 JP6339366B2 (ja) | 2018-06-06 |
Family
ID=44902091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508489A Expired - Fee Related JP6339366B2 (ja) | 2010-05-06 | 2011-05-04 | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
| JP2016197813A Expired - Fee Related JP6435583B2 (ja) | 2010-05-06 | 2016-10-06 | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016197813A Expired - Fee Related JP6435583B2 (ja) | 2010-05-06 | 2016-10-06 | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8871491B2 (enExample) |
| EP (2) | EP3281639B1 (enExample) |
| JP (2) | JP6339366B2 (enExample) |
| KR (2) | KR101916290B1 (enExample) |
| CN (1) | CN103079591B (enExample) |
| AU (2) | AU2011249839B2 (enExample) |
| CA (1) | CA2798381C (enExample) |
| CY (1) | CY1119895T1 (enExample) |
| DK (1) | DK2566507T3 (enExample) |
| ES (2) | ES2657588T3 (enExample) |
| HR (1) | HRP20180064T1 (enExample) |
| HU (1) | HUE037956T2 (enExample) |
| IL (1) | IL222711B (enExample) |
| LT (1) | LT2566507T (enExample) |
| NO (1) | NO2566507T3 (enExample) |
| PL (1) | PL2566507T3 (enExample) |
| PT (1) | PT2566507T (enExample) |
| SG (1) | SG185433A1 (enExample) |
| SI (1) | SI2566507T1 (enExample) |
| WO (1) | WO2011138361A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1481057E (pt) * | 2002-03-07 | 2006-05-31 | Eidgenoess Tech Hochschule | Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota |
| LT2257307T (lt) | 2008-02-20 | 2018-08-10 | Glaxosmithkline Biologicals S.A. | Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių |
| CN102724997B (zh) | 2009-11-19 | 2016-09-21 | 格林考瓦因有限公司 | 在原核细胞中产生免疫原性多糖的生物合成系统 |
| WO2013159234A1 (en) | 2012-04-27 | 2013-10-31 | The Governors Of The University Of Alberta | Glycoengineered outer membrane vesicles and use thereof as vaccines |
| WO2014013375A1 (en) | 2012-07-16 | 2014-01-23 | Pfizer Inc. | Saccharides and uses thereof |
| EP2877205A4 (en) | 2012-07-26 | 2016-04-06 | Jackson H M Found Military Med | VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY |
| ES2720040T3 (es) | 2012-10-12 | 2019-07-17 | Glaxosmithkline Biologicals Sa | Procedimientos de modificación de células hospedadoras |
| US20150273043A1 (en) | 2012-11-07 | 2015-10-01 | Glycovaxyn Ag | Production of recombinant vaccine in e.coli by enzymatic conjugation |
| CA2923957C (en) | 2013-01-18 | 2021-08-31 | London School Of Hygiene And Tropical Medicine | Glycosylation method |
| GB201301085D0 (en) * | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
| CA2926523C (en) * | 2013-10-11 | 2023-09-26 | Glycovaxyn Ag | Methods of host cell modification |
| JP2016540764A (ja) * | 2013-12-04 | 2016-12-28 | グリコヴァキシン アーゲー | 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防 |
| HUE049806T2 (hu) * | 2014-04-17 | 2020-10-28 | Glaxosmithkline Biologicals Sa | Módosított gazdasejtek és alkalmazásaik |
| US10307474B2 (en) * | 2014-08-08 | 2019-06-04 | Glaxosmithkline Biologicals S.A. | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| AU2015342943B2 (en) * | 2014-11-05 | 2018-06-28 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against Campylobacter jejuni |
| US10500261B2 (en) | 2014-11-05 | 2019-12-10 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| DK3240895T3 (da) | 2014-12-30 | 2022-04-11 | Glaxosmithkline Biologicals Sa | Sammensætninger og fremgangsmåder til proteinglykosylering |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US20200030430A1 (en) * | 2015-07-01 | 2020-01-30 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| CN108330142B (zh) * | 2018-02-09 | 2021-09-17 | 河北科技师范学院 | 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白 |
| GB201802339D0 (en) | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CN109400704B (zh) * | 2018-11-14 | 2020-07-21 | 珠海泰诺麦博生物技术有限公司 | 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用 |
| EP3894431A2 (en) | 2018-12-12 | 2021-10-20 | GlaxoSmithKline Biologicals SA | Modified carrier proteins for o-linked glycosylation |
| CN113646438A (zh) * | 2019-01-11 | 2021-11-12 | 西北大学 | 在原核生物细胞裂解物中合成生物缀合物疫苗 |
| EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| PL4010467T3 (pl) | 2019-08-09 | 2024-08-05 | Glaxosmithkline Biologicals Sa | Zmutowane enzymy oligosacharylotransferazy pglb |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN112575041B (zh) * | 2019-09-30 | 2022-12-13 | 江南大学 | 一种混合碳源高效发酵生产phb的工程菌及其应用 |
| CN115996749A (zh) | 2020-06-25 | 2023-04-21 | 葛兰素史克生物有限公司 | 经修饰的外毒素a蛋白 |
| CN114085255B (zh) * | 2020-08-24 | 2023-08-29 | 山东大学 | 一种苏黎世克罗诺杆菌5型脂多糖o-抗原寡糖片段及其制备方法与应用 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022171679A2 (en) | 2021-02-11 | 2022-08-18 | Glaxosmithkline Biologicals Sa | Protein |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
| WO2024002331A1 (en) * | 2022-06-30 | 2024-01-04 | Shanghai Yuguan Biotech Co., Ltd. | A live bacteria strain with reduced capsules |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025032534A2 (en) | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
| WO2025032535A2 (en) | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
| CN117771264B (zh) * | 2023-11-27 | 2024-06-25 | 山东省农业科学院畜牧兽医研究所 | circHIF1α在制备抵御细菌感染的新型疫苗中的应用 |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
| CN120005900B (zh) * | 2025-01-21 | 2026-01-06 | 浙江大学 | FaCP5L1和FaCP5L3基因及其在调控果实成熟和采后保鲜品质中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1900A (en) | 1840-12-14 | Machine for extracting stumps | ||
| EP0170204B1 (de) | 1984-08-01 | 1991-09-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| AU6663294A (en) | 1993-05-14 | 1994-12-12 | Upjohn Company, The | Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase |
| US6503744B1 (en) | 1999-02-01 | 2003-01-07 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
| AU3508300A (en) | 1999-03-02 | 2000-09-21 | Human Genome Sciences, Inc. | Engineering intracellular sialylation pathways |
| EP1285072A2 (en) | 2000-05-12 | 2003-02-26 | Neose Technologies, Inc. | In vitro fucosylation recombinant glycopeptides |
| WO2002000856A2 (en) | 2000-06-30 | 2002-01-03 | Flanders Interuniversity Institute For Biotechnology (Vib) | Protein glycosylation modification in pichia pastoris |
| KR20100119905A (ko) | 2002-03-07 | 2010-11-11 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계 |
| PT1481057E (pt) | 2002-03-07 | 2006-05-31 | Eidgenoess Tech Hochschule | Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota |
| US7598354B2 (en) | 2002-08-01 | 2009-10-06 | National Research Council Of Canada | Campylobacter glycans and glycopeptides |
| EP1756149B1 (en) | 2004-05-24 | 2013-09-04 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Live, oral vaccine for protection against shigella dysenteriae serotype 1 |
| DK1888761T3 (da) | 2005-05-11 | 2010-11-01 | Eth Zuerich | Rekombinante N-glycosylerede proteiner fra prokaryote celler |
| EP1998802A2 (en) | 2006-03-30 | 2008-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| WO2009089396A2 (en) * | 2008-01-08 | 2009-07-16 | Neose Technologies, Inc. | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| LT2257307T (lt) * | 2008-02-20 | 2018-08-10 | Glaxosmithkline Biologicals S.A. | Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių |
-
2011
- 2011-05-04 JP JP2013508489A patent/JP6339366B2/ja not_active Expired - Fee Related
- 2011-05-04 EP EP17192866.6A patent/EP3281639B1/en active Active
- 2011-05-04 HU HUE11724567A patent/HUE037956T2/hu unknown
- 2011-05-04 CN CN201180033560.1A patent/CN103079591B/zh not_active Expired - Fee Related
- 2011-05-04 AU AU2011249839A patent/AU2011249839B2/en not_active Ceased
- 2011-05-04 CA CA2798381A patent/CA2798381C/en active Active
- 2011-05-04 WO PCT/EP2011/057111 patent/WO2011138361A1/en not_active Ceased
- 2011-05-04 ES ES11724567.0T patent/ES2657588T3/es active Active
- 2011-05-04 PL PL11724567T patent/PL2566507T3/pl unknown
- 2011-05-04 NO NO11724567A patent/NO2566507T3/no unknown
- 2011-05-04 DK DK11724567.0T patent/DK2566507T3/da active
- 2011-05-04 LT LTEP11724567.0T patent/LT2566507T/lt unknown
- 2011-05-04 PT PT117245670T patent/PT2566507T/pt unknown
- 2011-05-04 SI SI201131403T patent/SI2566507T1/en unknown
- 2011-05-04 US US13/100,603 patent/US8871491B2/en active Active
- 2011-05-04 EP EP11724567.0A patent/EP2566507B1/en active Active
- 2011-05-04 SG SG2012081535A patent/SG185433A1/en unknown
- 2011-05-04 HR HRP20180064TT patent/HRP20180064T1/hr unknown
- 2011-05-04 KR KR1020187004586A patent/KR101916290B1/ko not_active Expired - Fee Related
- 2011-05-04 ES ES17192866T patent/ES2844596T3/es active Active
- 2011-05-04 KR KR1020127031847A patent/KR20130063510A/ko not_active Ceased
-
2012
- 2012-10-25 IL IL222711A patent/IL222711B/en active IP Right Grant
-
2014
- 2014-09-23 US US14/494,150 patent/US9585950B2/en not_active Expired - Fee Related
-
2016
- 2016-07-25 AU AU2016208265A patent/AU2016208265A1/en not_active Abandoned
- 2016-10-06 JP JP2016197813A patent/JP6435583B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-25 US US15/414,900 patent/US10307473B2/en active Active
-
2018
- 2018-02-06 CY CY20181100148T patent/CY1119895T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013524844A5 (enExample) | ||
| JP2017036303A5 (enExample) | ||
| Bitrus et al. | Staphylococcus aureus: A review of antimicrobial resistance mechanisms | |
| JP2015214545A5 (enExample) | ||
| NZ591925A (en) | Adjuvant composition comprising a host defense peptide, an immunostimulatory sequence and a polyanionic polymer | |
| SI2566507T1 (en) | Bioconjugate vaccines of capsular Gram-positive bacteria | |
| FI3110441T3 (fi) | Uusi polysakkaridi ja sen käyttöjä | |
| EP4245320A3 (en) | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli | |
| JP2014042533A5 (enExample) | ||
| JP2015533511A5 (enExample) | ||
| JP2017529849A5 (enExample) | ||
| JP2009527226A5 (enExample) | ||
| HRP20201021T1 (hr) | Modificirane stanice domaćini i njihova upotreba | |
| JP2010284165A5 (enExample) | ||
| JP2011502165A5 (enExample) | ||
| JP2010539256A5 (enExample) | ||
| Schroll et al. | Polyamines are essential for virulence in Salmonella enterica serovar Gallinarum despite evolutionary decay of polyamine biosynthesis genes | |
| JP2013531491A5 (enExample) | ||
| PH12019500843A1 (en) | Vaccine contructs and uses thereof against staphylococcus infections | |
| Loewen et al. | Genome sequence of a tigecycline-resistant clinical isolate of Acinetobacter baumannii strain AB031 obtained from a bloodstream infection | |
| Rojas et al. | Draft genome of a Brazilian avian-pathogenic Escherichia coli strain and in silico characterization of virulence-related genes | |
| EP4110793A1 (en) | Genetically engineered microorganisms that overexpress microcin-mge and methods of purification and use | |
| WO2010115278A8 (en) | Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection | |
| JP2013512675A5 (enExample) | ||
| JP2017537941A5 (enExample) |